Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
XC-8 by Valenta Pharm for Acute Bronchitis: Likelihood of Approval
XC-8 is under clinical development by Valenta Pharm and currently in Phase III for Acute Bronchitis. According to GlobalData, Phase...
XC-8 by Valenta Pharm for Viral Respiratory Tract Infection: Likelihood of Approval
XC-8 is under clinical development by Valenta Pharm and currently in Phase III for Viral Respiratory Tract Infection. According to...
XC-8 by Valenta Pharm for Acute Upper Respiratory Tract Infections: Likelihood of Approval
XC-8 is under clinical development by Valenta Pharm and currently in Phase III for Acute Upper Respiratory Tract Infections. According...
XC-8 by Valenta Pharm for Dry Cough: Likelihood of Approval
XC-8 is under clinical development by Valenta Pharm and currently in Phase III for Dry Cough. According to GlobalData, Phase...
XC-8 by JSC Valenta Pharmaceuticals for Acute Bronchitis: Likelihood of Approval
XC-8 is under clinical development by JSC Valenta Pharmaceuticals and currently in Phase III for Acute Bronchitis. According to GlobalData,...
XC-8 by JSC Valenta Pharmaceuticals for Viral Respiratory Tract Infection: Likelihood of Approval
XC-8 is under clinical development by JSC Valenta Pharmaceuticals and currently in Phase III for Viral Respiratory Tract Infection. According...
XC-8 by JSC Valenta Pharmaceuticals for Acute Upper Respiratory Tract Infections: Likelihood of Approval
XC-8 is under clinical development by JSC Valenta Pharmaceuticals and currently in Phase III for Acute Upper Respiratory Tract Infections....
XC-8 by JSC Valenta Pharmaceuticals for Dry Cough: Likelihood of Approval
XC-8 is under clinical development by JSC Valenta Pharmaceuticals and currently in Phase III for Dry Cough. According to GlobalData,...